Loading...
The randomized DAPA-CKD trial showed that the sodium–glucose cotransporter-2 (SGLT-2) inhibitor dapagliflozin improved cardiovascular and renal outcomes in patients with chronic kidney disease (CKD); enrolled patients had proteinuria and baseline glomerular filtration rates between 25 and 75 mL/minute/1.73 m2 (NEJM JW Gen Med Nov 1 2020 and N Engl J Med 2020; 383:1436). In a new post hoc analysis, dapagliflozin's effects on hospitalizations were analyzed among 2900 patients with type 2 diabetes and 1400 patients without diabetes. Median follow-up was 2.4 years.
Patients who received dapagliflozin, compared with placebo recipients, had significantly fewer first hospitalizations (14% vs. 17% annually; number needed to treat, 35) and fewer days…